Form 4: Aquestive Therapeutics Director John Cochran Acquires Stock Options
SEC Form 4 Filing
Director John Cochran of Aquestive Therapeutics acquired 38,000 stock options on June 20, 2024, according to a Form 4 filing.
Summary
- A Form 4 filing reveals that John Cochran, a director at Aquestive Therapeutics, acquired 38,000 stock options on June 20, 2024.
- The exercise price of these options is $2.50.
- The options vest 100% on June 20, 2025, contingent upon Mr. Cochran's continuous service with the Issuer.
- The options expire on June 20, 2034.
- Following the reported transaction, Mr. Cochran directly owns 99,486 shares of common stock and 38,000 stock options.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard Form 4 filing indicating a director's acquisition of stock options. It doesn't inherently suggest positive or negative performance, but rather provides transparency.
Positives
- The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. This filing indicates a director's activity in the company's stock.
Stakeholder Impact
- Shareholders may view the director's stock option acquisition as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/20/2024 | Date of transaction: Acquisition of 38,000 stock options. |
| 06/20/2025 | Vesting date: 100% of the underlying shares vest, subject to continuous service. |
| 06/20/2034 | Expiration date of the stock options. |
| 06/24/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.